Weight Loss Drugs Changed Their Lives. Then They Lost Coverage.news2024-12-19T10:00:46+00:00December 19th, 2024|The New York Times|
Long a ‘Crown Jewel’ of Government, N.I.H. Is Now a Targetnews2024-12-02T01:11:12+00:00December 2nd, 2024|The New York Times|
Ozempic Could Prevent Diabetes. Should We Use It For That?news2024-11-13T23:00:30+00:00November 13th, 2024|The New York Times|
Mounjaro and Zepbound Are No Longer in Shortage, F.D.A. Saysnews2024-10-03T16:50:39+00:00October 3rd, 2024|The New York Times|
Is Obesity a Disease? It’s Complicated in the Age of Ozempic.news2024-09-19T10:55:46+00:00September 19th, 2024|The New York Times|
Eli Lilly’s Popular Weight Loss Drug, Zepbound, Is Getting a Price Cutnews2024-08-27T10:45:07+00:00August 27th, 2024|The New York Times|
Compounded Semaglutide: What to Know About Overdose Risks of Ozempic Alternativenews2024-08-06T15:00:05+00:00August 6th, 2024|The New York Times|
Las versiones falsas de Ozempic van en aumentonews2024-07-18T09:03:31+00:00July 18th, 2024|The New York Times|
Fake Ozempic Is Putting Patients at Risk. Here’s How to Spot It.news2024-07-12T17:33:06+00:00July 12th, 2024|The New York Times|
